Zydus Lifesciences’ Verapamil Approval Analyzed

Zydus Lifesciences has achieved a significant milestone: the US Food and Drug Administration (USFDA) has officially approved their Verapamil Hydrochloride Extended-Release Tablets. These tablets, available in strengths of 120 mg, 180 mg, and 240 mg, are used to treat high blood pressure. Controlling high blood pressure is a key step in preventing serious heart issues like strokes and heart attacks.

Key Points

• Zydus gained USFDA approval for Verapamil Hydrochloride.
• Tablets treat high blood pressure effectively, preventing health risks.
• 120, 180, and 240mg strengths are now available.
• Production occurs in Baddi, Himachal Pradesh, India.
• Annual US sales reach $24.5 million (IQVIA data).
• This expands Zydus’s portfolio and market reach.

These Verapamil tablets are manufactured at Zydus Lifesciences’ facility in Baddi, Himachal Pradesh, India. The approval allows Zydus to sell these tablets directly to patients in the United States. Recent IQVIA data shows the tablets generated approximately $24.5 million in sales during the period of September 2025.

This approval represents a positive development for Zydus Lifesciences and strengthens its position in the pharmaceutical market. Ultimately, this signifies an opportunity to improve patient outcomes and contribute to cardiovascular health.

“Strategic approvals like this demonstrate Zydus’s commitment to delivering vital medications worldwide.”